ESSIG STUART 4
4 · INTEGRA LIFESCIENCES HOLDINGS CORP · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
Integra (IART) CEO Stuart Essig Receives Equity Awards
What Happened
Stuart Essig, President, CEO and a director of Integra LifeSciences Holdings Corp. (IART), was granted equity awards on 2026-06-01 consisting of 705,468 stock options and 365,297 restricted stock units (RSUs) — 1,070,765 awards in total. The reported acquisition price for these awards is $0 (these are compensation grants, not open-market purchases). The awards were made under the company's equity incentive plan and vest as to one-third on the first anniversary of 5/1/2026, with the remainder vesting monthly over the following 24 months, subject to continued service.
Key Details
- Transaction date: 2026-06-01; Filing date: 2026-06-03 (filed two days after the grant).
- Award breakdown: 705,468 stock options; 365,297 RSUs (total 1,070,765). Acquisition price reported as $0.
- Vesting: 1/3 vest on 5/1/2027, remainder monthly over the next 24 months (subject to continued service).
- Footnotes: Options consist of 482,976 granted under the executive employment agreement and 222,492 discretionary by the Compensation Committee. RSUs consist of 255,265 under the employment agreement and 110,032 discretionary. All awards are granted under the company’s Equity Incentive Plan.
- Shares owned after transaction: not specified in the filing.
- No immediate sale or exercise reported (these are grants/awards).
Context
RSUs represent a contingent right to receive one share per unit when vested; stock options give the right to purchase shares subject to their exercise terms. These awards are standard compensation for executives and are not open-market purchases or sales, so they reflect compensation decisions rather than direct buy/sell bets by the insider. The filing appears timely (filed within two business days of the grant).
Insider Transaction Report
- Award
Non-Qualified Stock Option (right to buy)
[F1]2026-06-01+705,468→ 705,468 totalExercise: $15.67Exp: 2034-06-01→ Common Stock (705,468 underlying) - Award
Restricted Stock Units
[F2][F3]2026-06-01+365,297→ 365,297 total→ Common Stock (365,297 underlying)
Footnotes (3)
- [F1]This award consists of (x) 482,976 stock options granted pursuant to the equity award provisions of the Reporting Person's employment agreement with the Issuer (the "Employment Agreement"), and (y) 222,492 stock options granted at the discretion of the Compensation Committee of the Issuer's Board of Directors (the "Compensation Committee"). All stock options reported in this row were granted under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan") and will vest as to one-third of such stock options on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.
- [F2]Grant of restricted stock units ("RSUs") pursuant to the Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F3]This award consists of (x) 255,265 RSUs granted pursuant to the equity award provisions of the Employment Agreement, and (y) 110,032 RSUs granted at the discretion of the Compensation Committee. All RSUs reported in this row were granted under the Plan and will vest as to one-third of the shares on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.